Medexus Announces New License Deal for Topical Terbinafine
TORONTO and CHICAGO, March 22, 2023 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased to announce that the company has secured Canadian rights to commercialize terbinafine hydrochloride nail lacquer supplied by Polichem, an Almirall group company focused on medical dermatological treatments for skin health. The product, which Medexus will submit for Health Canada approval later this year, has been widely used in other markets to treat fungal nail infections. Medexus estimates the total value of the Canadian fungicides market to be C$88 million annually.*
Related news for (MEDXF)
- Medexus to Participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference
- Medexus Expects Record Revenue for Fiscal Year 2023 and Provides Business Update
- Medexus Announces US$58.5 million in New Credit Facilities
- Medexus Announces Another Record Quarter with Fiscal Q3 2023 Revenue of US$28.7 Million, a 35% Increase Over Fiscal Q3 2022